641571-03-1

Basic information

• Product Name: N-BOC-3-BROMO-5-TRIFLUOROMETHYLANILINE
• Synonyms: N-BOC-3-BROMO-5-TRIFLUOROMETHYLANILINE;t-Butyl 3-bromo-5-(trifluoromethyl)phenylcarbamate
• CAS NO: 641571-03-1
• Molecular Formula: C₁₂H₁₃BrF₃NO₂
• Molecular Weight: 340.15
• Mol File: 641571-03-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-BOC-3-BROMO-5-TRIFLUOROMETHYLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-3-BROMO-5-TRIFLUOROMETHYLANILINE(641571-03-1)
• EPA Substance Registry System: N-BOC-3-BROMO-5-TRIFLUOROMETHYLANILINE(641571-03-1)

Safety Data

• Hazardous Substances Data: 641571-03-1(Hazardous Substances Data)

Usage

General Description

N-BOC-3-Bromo-5-trifluoromethylaniline is a chemical compound that belongs to the category of organic compounds known as anilides. N-BOC-3-BROMO-5-TRIFLUOROMETHYLANILINE contains a structure of aniline carrying an acyl substituent at its amino group. Often used for various chemical and pharmaceutical applications, it is typically characterized by special properties such as its molecular weight, melting point, boiling point, and density, among others. Its precise structure and composition are outlined by its systematic IUPAC name, 1-(3-bromo-5-(trifluoromethyl)phenyl)-2-methoxy-2-oxoethyl-λ5-azane.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 54962-75-3 [3-bromo-5-(trifluoromethyl)phenyl]amine 

Downstream Products

• 1207351-03-8 5-trifluoromethyl-3-(tert-butyl-oxycarbonyl)amino-phenylboronic acid 
• 1072710-87-2 3-(3-methyl-3H-imidazol-4-yl)-5-trifluoromethyl-phenylamine 
• 1072710-96-3 [3-(3-methyl-3H-imidazol-4-yl)-5-trifluoromethyl-phenyl]-carbamic acid tert-butyl ester 
• 641571-21-3 3-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)benzenamine 

Relevant articles and documents

DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumor diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.